

Clinical documentation of Thyroid Eye Disease (TED) signs and symptoms

Consider including this in the patient's medical record to monitor symptoms of disease activity

Patient name: _____ Date of birth: _____ Weight: _____ Date: _____
 (mm/dd/yyyy) (lb) (mm/dd/yyyy)

CLINICAL ACTIVITY SCORE^{1*}

The Clinical Activity Score (CAS) is a tool designed to evaluate inflammatory signs and symptoms that are often characteristic of TED, also known as Graves' orbitopathy. The score can be used as one part of the overall assessment of TED.

How to use CAS: 1 point is given for each sign or symptom. CAS ≥ 3 indicates inflammatory disease.		Baseline exam	Follow-up assessments
Date (mm/dd/yyyy)		___/___/___	___/___/___
1	Spontaneous orbital pain		
2	Gaze-evoked orbital pain		
3	Eyelid swelling		
4	Eyelid erythema		
5	Conjunctival redness		
6	Chemosis		
7	Inflammation of caruncle or plica		
For baseline CAS, total lines 1-7			
8	Increase of ≥ 2 mm in proptosis		
9	Decreased eye movements $> 8^\circ$ in any direction		
10	Decrease in acuity ≥ 1 Snellen line		
For follow-up CAS, total lines 1-10			

*The CAS is a composite score with equal weighting of a number of factors; however, the factors may not be of equal clinical weight either to the patient or to the physician. While CAS is a useful tool for diagnosis and monitoring of patients, some patients may not present with characteristic signs of TED and may require additional evaluation.

THYROID FUNCTION

Does the patient have stable thyroid levels? Yes No

Is the patient undergoing treatment to correct and/or maintain thyroid state? Yes No

Thyroid labs:
Free thyroxine (free T4) levels: _____

Free triiodothyronine (free T3) levels: _____

Patient name: _____

Date of birth: _____

Date: _____

(mm/dd/yyyy)

(mm/dd/yyyy)

SEVERITY OF TED SYMPTOMS^{7,8}

To determine whether symptoms are mild, moderate, or severe/vision threatening, document symptom changes with the American Thyroid Association® Graves' Orbitopathy Severity Assessment.

Fill in the information based on criteria used in the table below:	Lid retraction: _____	Proptosis: _____	Corneal exposure: _____
	Soft tissue involvement: _____	Diplopia: _____	Optic nerve status: _____

Grade*	Lid retraction	Soft tissues	Proptosis†	Diplopia	Corneal exposure	Optic nerve status
Mild	<2 mm	Mild involvement	<3 mm	Transient or absent	Absent	Normal
Moderate-to-severe	≥2 mm	Moderate or severe involvement	≥3 mm	Inconstant or constant	Mild	Normal
Sight threatening	—	—	—	—	Severe	Compression

Upper limits of normal: Measure degree of proptosis according to values below or any available patient baselines

African American	F/M = 23/24 mm
White	F/M = 19/21 mm
Asian	F/M = 16/17 mm (Thai) or 18.6 mm (Chinese)

The publisher for this copyrighted material is Mary Ann Liebert, Inc. publishers.

Sources: Adapted from de Juan et al. (3) Sarinapakorn et al. (4) Tsai et al. (5) and Bartalena et al. (6).

*Mild Graves' orbitopathy (GO): patients whose features of GO have only a minor impact on daily life, generally insufficient to justify immunosuppressive or surgical treatment. Moderate-to-severe GO: patients without sight-threatening GO whose eye disease has sufficient impact on daily life to justify the risks of immunosuppression (if active) or surgical intervention (if inactive). Sight-threatening GO: patients with dysthyroid optic neuropathy and/or corneal breakdown and/or globe subluxation. This category warrants immediate intervention.⁷

†Proptosis refers to the variation compared to the upper limit of normal for each race/sex or the patient's baseline, if available.⁷

DOCUMENTATION OF PREVIOUS TREATMENT(S)

Fill out the table below to document the patient's previous treatment(s) for TED.

	Date range	Ineffective?	Not tolerated?	Contraindicated?
Eye drops				
Steroids <input type="checkbox"/> Oral <input type="checkbox"/> IV Dose: _____				
Biologics				
Other				

OTHER FACTORS

History of Diabetes? Yes No

Inflammatory bowel disease? Yes No

Pregnant? Yes No

Birth control? Yes No

Graves' disease associated with TED? Yes No Other _____

Physician signature: _____ Date: _____
(mm/dd/yyyy)